Posted by Michael Wonder on 08 Nov 2021
FDA grants tentative approval for Liquidia’s Yutrepia (treprostinil) inhalation powder
8 November 2021 - Final FDA approval may occur in October 2022 or earlier upon resolution of on-going litigation.
Liquidia Corporation announced today that the U.S. FDA granted tentative approval for Yutrepia (treprostinil) inhalation powder, previously referred to as LIQ861.
